益生菌与合生元补充对2型糖尿病风险成人代谢综合征指标的影响:随机对照试验研究方案
该研究为在伊朗开展的三盲随机对照试验方案,计划纳入120名糖耐量受损成人,随机分配接受6克/天益生菌、合生元或安慰剂干预6个月,评估粪便细菌丰度、血压、人体测量指标、血脂谱、HbA1C、空腹血糖、胰岛素水平及HOMA-IR和HOMA-B,并在基线及第3、6、12、18个月重复测量。作者假设选择性调节肠道菌群可能改善代谢功能障碍并预防糖尿病。
要点
- 三盲随机对照试验,120名糖耐量受损成人随机接受益生菌、合生元或安慰剂6个月。
- 结局包括粪便细菌丰度、血压、人体测量指标、血脂谱、HbA1C、空腹血糖、胰岛素及HOMA-IR和HOMA-B。
- 测量时间点为基线及第3、6、12、18个月。
核心结论
- 作者假设通过益生菌或合生元补充选择性调节肠道菌群可能改善代谢功能障碍并预防糖尿病前期患者进展为糖尿病。
- 该试验结果可能有助于制定针对肠道菌群调控以最大化糖尿病前期代谢综合征预防和管理健康获益的循证临床指南。
研究设计与样本
- 随机三盲对照临床试验,计划纳入120名符合纳入标准的糖耐量受损成人,采用简单随机抽样方法选取并随机分配至6克/天益生菌组、合生元组或安慰剂组,干预6个月。
- 在基线及治疗后测量粪便细菌丰度、血压、身高、体重、腰围和臀围。
- 在基线及第3、6、12、18个月测量血浆血脂谱、HbA1C、空腹血糖和胰岛素水平,并计算胰岛素抵抗(HOMA-IR)和β细胞功能(HOMA-B)。
关键数值与推荐
- 干预剂量为6克/天,干预时长6个月。
- 测量时间点为基线及第3、6、12、18个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of type 2 diabetes, cardiovascular diseases, and obesity has been rising dramatically; however, their pathogenesis is particularly intriguing. Recently, dysbiosis of the intestinal microbiota has emerged as a new candidate that may be linked to metabolic diseases. We hypothesize that selective modulation of the intestinal microbiota by probiotic or synbiotic supplementation may improve metabolic dysfunction and prevent diabetes in prediabetics. In this study, a synthesis and study of synbiotics will be carried out for the first time in Iran. METHODS/DESIGN: In a randomized triple-blind controlled clinical trial, 120 adults with impaired glucose tolerance based on the inclusion criteria will be selected by a simple random sampling method and will be randomly allocated to 6 months of 6 g/d probiotic, synbiotic or placebo. The fecal abundance of bacteria, blood pressure, height, weight, and waist and hip circumferences will be measured at baseline and following treatment. Also, plasma lipid profiles, HbA1C, fasting plasma glucose, and insulin levels, will be measured and insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) will be calculated at baseline and will be repeated at months 3, 6, 12, and 18. The data will be compared within and between groups using statistical methods. DISCUSSION: The results of this trial could contribute to the evidence-based clinical guidelines that address gut microbiota manipulation to maximize health benefits in prevention and management of metabolic syndrome in prediabetes. TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT201511032321N2 . Registered on 27 February 2016.
引用
- Kassaian N, Aminorroaya A, Feizi A, et al. The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28356129. doi:10.1186/s13063-017-1885-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。